Simultaneous portal and hepatic vein embolization before major liver resection

Guiu et al. [15, 25] called his technique a “deprivation of liver veins”, because he did not only place AVPs in the larger hepatic veins, but also filled the smaller contributories with a mixture of N-butyl-cyanoacrylate and iodized oil (NBCA/lipiodol). In LVD, the right portal vein is embolized—without segment 4 embolization—and during the same session, the right hepatic vein is occluded by the use of AVPs followed with the addition liquid embolization with NBCA/lipidol of the small hepatic veins flowing to the AVPs. In a technically impressive and perfectionist approach, even visible venous collaterals that arise even during the procedure are embolized. In the subsequent article, Guiu et al. [25] then demonstrated a modified version of the LVD, the so-called extend liver venous deprivation (eLVD). eLVD provides an additional occlusion of the right middle hepatic vein using AVPs and NBCA/lipiodol. The eLVD technique, a “turbo” version of LVD in terms of hypertrophy was used in 4 further published series in a limited number of cases (Table 1) [26, 29‐31]. Impressively, the Montpellier LVD technique is already being tested in an ongoing randomized controlled trail (RCT) of 8 centers in France (NCT03995459). However, the majority of published articles, which are not from the Montpellier group, except one article from Bordeaux, [31] did not use the additive liquid embolization of hepatic veins following AVP occlusion, but only placed AVPs without much attention to the small veins flowing to the AVPs (Table 1) [26, 27, 29, 30]. Also, the Montpellier group used a transhepatic approach for the hepatic vein embolization [15, 25, 28], which has also been adopted by the Bordeaux group [31]. All other groups use the more common transjugular approach as their standard method [26, 27, 29, 30].

Two studies proposed the new name “bi-embolization” to their version of PVE/HVE performed without liquid embolization of smaller contributories [26, 30]. In contrast, the Lausanne group calls their approach “LVD”, while they did not actually use liquid embolization. In certain sense, “LVD” for procedures without liquid embolization is a misnomer [29]. The Bordeaux group in contrast actually used an additional liquid embolization like the LVD technique and should have called their technique “LVD”, but unfortunately created yet another name, “RASPE” (radiological simultaneous portohepatic vein embolization) [31].

In a Delphi process leading to the collaborative Dragon trial (DRAGON: NCT04272931), a decision among participating centers was made to refrain from the additional liquid embolization of small contributories due to the perceived risk of liquid embolization of the venous system, the right heart circulation and the lungs. Figure 1 shows a CT scan of a patient using multiple AVPs for right-sided hepatic vein embolization. However, to avoid further confusion, the generic descriptive PVE/HVE was used for the procedure.

Taking all published series into account, 132 patients underwent PVE/HVE to increase the FLR prior to surgery [15, 25‐31]. Mean or median time between PVE/HVE and surgery ranges between 21 [27] and 49 days (interquartile range (IQR) 20–210) [26], while one series did not report this time interval at all [30] (Table 2). During that interval, 16 patients developed progression of disease [15, 26, 27, 29‐31], and in one patient, liver function growth was insufficient [25]. Overall, 115 of 132 patients (87%) achieved surgical resection after PVE/HVE, resulting in a drop-off rate of 13% [15, 25‐31].

In the studies where PVE/HVE was compared with PVE, surgery was performed between a mean or median of 21 [27] to 45 days (standard deviation (SD) ± 5) [31] after PVE, showing no difference between PVE/HVE and PVE (Table 4) [27‐29, 31]. Again, one series did not report on that interval [30]. For PVE, resectability ranges between 76 [30] and 94% [28]. In two comparative series, the feasibility of resection after PVE/HVE vs. PVE was not specifically analyzed due to the small study size [27, 28]. However, in the remaining 3 comparative series, no difference was seen in resectability between both approaches [29‐31].

The importance of the endpoint feasibility of resection to assess methods of regenerative liver surgery was recently demonstrated by the Scandinavian LIGRO trial (NCT02215577)—the first RCT of ALPPS vs. TSH [33]. Patients with borderline resectable CRLM were randomized either to ALPPS or TSH with a PVL during the first stage or a PVE between the stages. Patients included in this trial were highly selected and received induction chemotherapy. Both approaches, ALPPS and TSH demonstrated a relatively high morbidity (43% major complications (≥ IIIa) in both procedures) and high mortality (ALPPS: 9.1% vs. TSH: 10.7%). However, patients who underwent ALPPS had a 92% vs. 57% (TSH) resectability (p < 0.001). While in the ALPPS cohort patients underwent both stages within a mean of 11 days (SD ± 11), in the TSH cohort the second stage was performed after a mean of 43 days (SD ± 15) due to the slower hypertrophy (p < 0.001). During that time, 16% in the TSH cohort had tumor progression, and 27% demonstrated insufficient liver growth. Interestingly, in a follow-up evaluation [34], the ALPPS cohort also demonstrated an improved median survival of 46 months compared with 26 months after TSH (p = 0.028). For the first time, the LIGRO trial demonstrated an effect of a surgical resection technique on survival in metastases surgery based on randomized data. It appears as if rapid resection of the entire tumor load in CRLM matters.

The interventional radiology procedure PVE/HVE was successfully performed in all 132 patients in the published series, and no severe adverse events were reported (Table 1) [15, 25‐31]. No difference of complications after the intervention itself was reported in the 5 comparative series between PVE/HVE and PVE [27‐31]. Theoretical concerns about liver necrosis due to the simultaneous occlusion of the hepatic in- and outflow were not observed in these initial clinical reports [15]. As far as the effect of PVE/HVE on the liver is concerned, 8 days after LVD the transaminases remain slightly elevated, but there was no sign of liver necrosis in histology, which was confirmed by two further studies [28, 31]. It has to be assumed that the devascularized lobe remains viable by arterial blood flow alone [35]. It has to be postulated that new venous outflow collaterals enable the drainage of the arterial blood [36]. In any case, arterial blood flow appears sufficient to avoid liver necrosis at a larger scale.

The majority of patients who underwent PVE/HVE as preparation later underwent a major hepatectomy (Table 2) [15, 25‐30]. Seven of 8 series reported on the postoperative complications of this hepatectomy using the Dindo-Clavien classification [15, 25, 26, 28‐31], while one comparative study did not provide information about the postoperative outcome according to the Dindo-Clavien classification [27]. In these 7 series, 111 patients underwent surgery after PVE/HVE [15, 25, 26, 28‐31]. Overall complications occurred in 75 of those (68%), while complications at least III were reported in 23 patients (21%). PHLF occurred in 5 patients (5%) [27, 28]. In one series, 50–50 criteria were used of assessment [27], while the other studies defined PHLF according to the International Study Group of Liver Surgery (ISGLS) criteria [28].

All series except one [31] reported their mortality [15, 25‐30], but two series did not mention if perioperative mortality rate referred to the 30- or 90-day mortality [28, 29]. Of the 111 patients who underwent surgery after PVE/HVE, 5 patients died in the postoperative course, resulting in a mortality rate of 5% [15, 26, 30]. One series reported that one of 6 patients died 10 days after surgery due to postoperative pneumonia [15]. In another study, one patient died 10 days after coiling of the common hepatic artery for postoperative hemorrhage [26]. No further information was provided on the death of 3 more patient within 90 days after resection [30].

When morbidity and mortality of PVE/HVE were compared with PVE in the comparative studies, no difference was observed between the two (Tables 2 and 4) [27‐31]. However, one series demonstrated a difference in the occurrence of PHLF between PVE/HVE (0%) and PVE (23%) (p = 0.012) [31].

Interestingly, all of these mortalities after both ALPPS and TSH were PHLF-related in the LIGRO trial [33]. Overall, 5 patients in all studies available so far developed PHLF following PVE/HVE (Table 2), but none of these cases resulted in a perioperative death [15, 26, 30].

All series report on the volume increase of the FLR after PVE/HVE (Table 3) [15, 25‐31], but a comparison between the series is difficult due to the inhomogeneity of metrics used to measure liver volume and growth. A standardization should be considered obligatory for future studies.

Standardized volumetric data by the use of biometric formulas for the sFLR are only provided by two studies [25, 29]. In the series comparing PVE/HVE with PVE, no significant difference was achieved in the sFLR after the respective interventions (Tables 3 and 4) [29]. However, the achieved percent hypertrophy was significantly different of the FLR (35% (IQR 23–54) vs. 24% (IQR 7–40) resp. p = 0.03). The same was shown by the comparative study from Clermont-Ferrand group [30], which unfortunately used the metrics “absolute FLR volume” in cubic centimeters (cc). While the liver volume did not differ after PVE/HVE and PVE, the percent hypertrophy (in cc) shows a significant difference: 51.2% (SD ± 41.7) vs. 31.9% (SD ± 34) (p = 0.018). The percent hypertrophy also differed between PVE/HVE and PVE in a recently published comparative series, but the starting FLR in the PVE control calls into question, if a regenerative maneuver was indicated in these patients at all [31].

To compare the novel PVE/HVE with PVE, the choice of the PVE control group really matters. The MD Anderson group has shown that PVE can be performed as low- or high-quality procedure [12]. In HQPVE, embolization segment 4 is added to right hemiliver embolization. Any new version of PVE like PVE/HVE has to be compared with HQPVE. In HQPVE, an increase of the sFLR of 20.1% (range: 9.5–57.8) to 29.4% (range: 20.1–75.1) within a median of 30 days should be considered to be the gold standard [37]. The same applies to the growth metrics “degree of hypertrophy (DH)”, which is defined as the sFLR after the intervention minus the sFLR prior to the invention. The DH of 8.9% (IQR 6.7–12.8) for PVE/HVE demonstrated by the Lausanne group [29] or the DH of 12.7% by the Montpellier group [15] have to be compared with 10.1% (0.1–39.9) after HQPVE as published by the MD Anderson group [37]. Unfortunately, the comparison is limited because the Lausanne [29] and Montpellier group [15] preferred to use FLRs instead of sFLR.

To estimate the speed of liver growth, the metrics “kinetic growth rate” (KGR) is routinely used, which is defined as the ratio between the DH and the elapsed time in weeks between embolization and first cross-sectional volumetry in sFLR/week [37]. Unfortunately, 2 series did not give any information about the KGR [27, 31], and in 2 further series, the calculation of the KGR is unclear [26, 30]. Two used percent of total liver volume increase per week as their metrics for kinetic growth (Table 3) [25, 28].

While the initial study from Montpellier reported a KGR of 4.2% sFLR/week for PVE/HVE after a median of 23 days (range: 13–30) [15], the MD Anderson group gave a KGR of 2.4% sFLR/week (range: 0.2–9.4) after a median of 30 days (range: 14–54) for PVE. Of note, 63% of patients underwent HQPVE in this study. Although the KGR after PVE/HVE was two times higher in the Montpellier group than that of HQPVE, it should be noted that the volumetric assessment was performed 7 days later at the MD Anderson [37], which may introduce a bias towards a higher KGR. Also, none of the patients reported from Montpellier had diabetes or underwent chemo before embolization, [15] while the MD Anderson report included patients with diabetes (6.8%) and chemotherapy (92.3%), which is known to reduce the KGR [7, 37, 38]. The Lausanne group demonstrates a KGR of 2.9% FLR/week (IQR 1.9–4.3) after a median of 22 days (IQR 17–30), while 50% of patients underwent chemotherapy [29].

The report by the Montpellier group about eLVD in 2017 reports a successive volume increase over 3 time points (7, 14, and 21 days) in 3 patients [25]. From day 0 to day 7, the FLR increased from a mean of 20.8% (SD ± 5.1) to a mean of 31.8% (SD ± 8.2) (53% hypertrophy from baseline). From day 7 to day 14, the FLR increased less dramatically from 31.8 to 33.4% (SD ± 7) (63% hypertrophy from baseline) and from day 14 to 21 from 33.4 to 33.4% (SD ± 6.7) (63% hypertrophy from baseline). The Scandinavian LIGRO trial also reports volume data after 7 days [33]. The percent hypertrophy in ml in patients suffering from CRLM was 68% (± 38) for ALPPS and 43% (± 30) for PVE or PVL. Looking at these data, PVE/HVE seems to be right in the middle between PVE and ALPPS [25].

There is evidence that ALPPS leads to an incongruent increase in volume and function using technetium-99 m hepatobiliary scintigraphy (^99mTc-mebrofenin HBS) [39, 40]. PVE/HVE has also been evaluated for functional changes using ^99mTc-mebrofenin HBS in 10 patients [25]. In 3 of those, who underwent eLVD, a serial measurement was performed at days 7, 14, and 21 (according to the volume assessment). Although, these data are based on a small patient sample size, a parallel increase was described in volume and function with a maximal function already at day 7 (65.7% (SD ± 16)). Afterwards, at day 14 and 21, the function does not demonstrate a further increase from baseline (14 days: 57% (SD ± 18) and 21 days: 57% (± 18).

Overall studies about PVE/HVE are characterized by a small study size and highly selected patients. Patients with diabetes for example have been underrepresented [30, 37]. Not more than 5 patients had liver cirrhosis, and only 6 patients had elevated bilirubin before embolization and needed a biliary drainage [27, 28, 30]. In 5 series, patients (n = 50) were reported to have received chemotherapy before embolization, but not all series provide information about the specific drugs used [25, 26, 28, 29, 31].

The question if PVE/HVE has long-lasting advantages over PVE can likely not be answered by cohort studies, but requires a RCT. Currently two studies are registered (International DRAGON trial: NCT04272931, LVD France trial: NCT03995459).